Abstract
Aim: Despite of huge development of molecular research and target agents, patients with EGFR wild type NSCLC who accounted for more than a half of NSCLC patients still have to receive platinum doublet chemotherapy in 1st line treatment. Because only a little research has been conducted with EGFR wild type NSCLC patients, we investigated efficacies of various platinum doublet regimens in these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
